Standout Papers

Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lym... 2017 2026 2020 2023 675
  1. Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma (2017)
    Robert Chen, Pier Luigi Zinzani et al. Journal of Clinical Oncology
  2. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study (2018)
    Antoîne Italiano, Jean‐Charles Soria et al. The Lancet Oncology

Immediate Impact

2 by Nobel laureates 17 from Science/Nature 65 standout
Sub-graph 1 of 20

Citing Papers

Natural killer cell therapies
2024 StandoutNature
Targeted protein degradation: from mechanisms to clinic
2024 Standout
2 intermediate papers

Works of Vincent Ribrag being referenced

Clinical Activity of CC-99282, a Novel, Oral Small Molecule Cereblon E3 Ligase Modulator (CELMoD) Agent, in Patients (Pts) with Relapsed or Refractory Non-Hodgkin Lymphoma (R/R NHL) - First Results from a Phase 1, Open-Label Study
2021
PD-1 Blockade with the Monoclonal Antibody Pembrolizumab (MK-3475) in Patients with Classical Hodgkin Lymphoma after Brentuximab Vedotin Failure: Preliminary Results from a Phase 1b Study (KEYNOTE-013)
2014
and 1 more

Author Peers

Author Last Decade Papers Cites
Vincent Ribrag 3486 4487 1659 1909 305 7.7k
Lorenz Trümper 3812 3200 2007 1870 197 7.3k
Michael Crump 5429 5150 2308 1572 300 9.5k
Marco Ladetto 4137 2884 1648 1561 170 7.0k
Sven de Vos 3851 3491 2528 2061 190 7.4k
Steven Le Gouill 3575 3199 1647 2102 304 7.0k
Cheolwon Suh 4603 4629 1122 939 407 7.6k
Francesc Bosch 5469 3354 4215 1916 240 8.5k
Lisa M. Rimsza 3417 2577 1516 1340 198 6.0k
Sonali M. Smith 4064 3254 2274 1268 262 6.6k
Luis Fayad 6166 5377 2647 1259 325 9.5k

All Works

Loading papers...

Rankless by CCL
2026